1
|
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol 2011; 63:1119-35. [DOI: 10.1111/j.2042-7158.2011.01279.x] [Citation(s) in RCA: 201] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Abstract
Objectives
Cyclodextrins are useful solubilizing excipients that have gained currency in the formulator's armamentarium based on their ability to temporarily camouflage undesirable physicochemical properties. In this context cyclodextrins can increase oral bioavailability, stabilize compounds to chemical and enzymatic degradation and can affect permeability through biological membranes under certain circumstances. This latter property is examined herein as a function of the published literature as well as work completed in our laboratories.
Key findings
Cyclodextrins can increase the uptake of drugs through biological barriers if the limiting barrier component is the unstirred water layer (UWL) that exists between the membrane and bulk water. This means that cyclodextrins are most useful when they interact with lipophiles in systems where such an UWL is present and contributes significantly to the barrier properties of the membrane. Furthermore, these principles are used to direct the optimal formulation of drugs in cyclodextrins. A second related critical success factor in the formulation of cyclodextrin-based drug product is an understanding of the kinetics and thermodynamics of complexation and the need to optimize the cyclodextrin amount and drug-to-cyclodextrin ratios. Drug formulations, especially those targeting compartments associated with limited dissolution (i.e. the eye, subcutaneous space, etc.), should be carefully designed such that the thermodynamic activity of the drug in the formulation is optimal meaning that there is sufficient cyclodextrin to solubilize the drug but not more than that. Increasing the cyclodextrin concentration decreases the formulation ‘push’ and may reduce the bioavailability of the system.
Conclusions
A mechanism-based understanding of cyclodextrin complexation is essential for the appropriate formulation of contemporary drug candidates.
Collapse
Affiliation(s)
- Thorsteinn Loftsson
- Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata, Reykjavik, Iceland
| | - Marcus E Brewster
- Pharmaceutical Development and Manufacturing Sciences, Janssen Research and Development, Johnson & Johnson, Scheperstraat, Beerse, Belgium
| |
Collapse
|
2
|
Barillaro V, Pescarmona PP, Van Speybroeck M, Thi TD, Van Humbeeck J, Vermant J, Augustijns P, Martens JA, Van Den Mooter G. High-Throughput Study of Phenytoin Solid Dispersions: Formulation Using an Automated Solvent Casting Method, Dissolution Testing, and Scaling-Up. ACTA ACUST UNITED AC 2008; 10:637-43. [DOI: 10.1021/cc8000585] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Valéry Barillaro
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Paolo P. Pescarmona
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Michiel Van Speybroeck
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Thao Do Thi
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Jan Van Humbeeck
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Jan Vermant
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Patrick Augustijns
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Johan A. Martens
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| | - Guy Van Den Mooter
- Laboratory for Pharmacotechnology and Biopharmacy, K.U. Leuven, Gasthuisberg O&N2, Herestraat 49, 3000 Leuven, Belgium, Centre for Surface Chemistry and Catalysis, K.U. Leuven, Kasteelpark Arenberg 23, 3001 Heverlee, Belgium, MTM Department, K.U. Leuven, Kasteelpark Arenberg 44, 3001 Heverlee, Belgium, and CIT Department, K.U. Leuven, Willem de Croylaan 46, 3001 Heverlee, Belgium
| |
Collapse
|
7
|
Latrofa A, Trapani G, Franco M, Serra M, Muggironi M, Fanizzi FP, Cutrignelli A, Liso G. Complexation of phenytoin with some hydrophilic cyclodextrins: effect on aqueous solubility, dissolution rate, and anticonvulsant activity in mice. Eur J Pharm Biopharm 2001; 52:65-73. [PMID: 11438425 DOI: 10.1016/s0939-6411(01)00144-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The main objective of this study was to evaluate the influence of hydroxypropylated beta- and gamma-cyclodextrins and Me-beta-cyclodextrin (HP-beta-CD, HP-gamma-CD, and Me-beta-CD, respectively) on the dissolution rate and bioavailability of the antiepileptic agent, phenytoin (DPH). The corresponding solid complexes were prepared by a freeze-drying method and characterized by infrared spectroscopy, X-ray powder diffraction, and differential scanning calorimetry studies. Evidence of inclusion complex formation in the case of HP-beta-CD was obtained by (1)H- and (13)C-nuclear magnetic resonance spectroscopy. Drug solubility and dissolution rate in 0.05 M potassium phosphate buffer (pH 6) were notably improved by employing the beta-CDs. Thus a 45% w/v HP-beta-CD or Me-beta-CD solution gave rise to an increase of dissolved drug of 420- and 578-fold, respectively. The Q(10) (i.e. percentage of dissolved DPH at 10 min) was 5.2% for the pure drug and 93, 98, and 96% for DPH/HP-beta-CD, DPH/HP-gamma-CD, and DPH/Me-beta-CD complexes, respectively. Moreover, it was found that in the maximal electroshock seizure test in mice the DPH/Me-beta-CD complex exhibited anticonvulsant activity similar to DPH sodium salt (NaDPH).
Collapse
Affiliation(s)
- A Latrofa
- Dipartimento Farmaco-Chimico, Facoltà di Farmacia, Università degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
| | | | | | | | | | | | | | | |
Collapse
|